Edgewise Therapeutics, Inc.(EWTX), a muscle disease biopharmaceutical company, on Wednesday announced the pricing of an underwritten offering of 9,935,419 shares at $20.13 per share. The offering is expected to close on April 3.
Shares of Edgewise are decreasing in the pre-market trading.
The company plans to use the net proceeds for the potential commercial launch of Sevasemten, once approved.
Sevasemten is a Phase 3 trial for Duchenne muscular dystrophy, advance Phase 3 trials of EDG-7500 for hypertrophic cardiomyopathy.
In the pre-market trading, Edgewise is 18.83% higher at $16.34 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.